Track topics on Twitter Track topics that are important to you
15.1% year-over-year increase in revenue
Electromed, Inc. (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended December 31, 2018 (Q2 FY 2019).
Q2 FY 2019 Highlights
Kathleen Skarvan, President and Chief Executive Officer of Electromed, commented, “We achieved more referrals and approvals compared to the same quarter in the prior year, reflecting our expanded sales force, ongoing excellence in our reimbursement operations and continuing efforts to advance physician awareness and education surrounding the benefits of high frequency chest wall oscillation therapy (HFCWO) with our SmartVest® device. In our institutional market, we achieved another quarter of strong revenue growth, driven primarily by our strategic focus on integrated delivery networks.”
Q2 FY 2019 Review
Net revenue increased 15.1% to $8.0 million, from $7.0 million in Q2 FY 2018, primarily driven by higher home care revenue. Home care revenue rose 13.0% to $7.3 million from $6.5 million in Q2 FY 2018, primarily due to growth in referrals and approvals driven by a larger field sales staff and continued improvements in the company’s reimbursement operations that led to a greater referral to approval percentage.
Gross profit increased 12.2% to $6.1 million, or 75.7% of net revenue, from $5.4 million, or 77.6% of net revenue, in Q2 FY 2018. The increase in gross profit resulted primarily from an increase in home care revenue. The decrease in gross profit as a percentage of net revenue was driven by a lower selling price per device in the company’s institutional market.
Operating expenses, which include selling, general and administrative (SG&A) as well as R&D expenses, totaled $5.4 million, or 67.3% of net revenue, compared with $4.6 million, or 66.5% of net revenue, in the same period of the prior year. SG&A expenses increased 12.6% to $5.2 million, from $4.6 million in Q2 FY 2018, primarily due to higher payroll and compensation-related expenses and increased travel, meals and entertainment expenses, which were driven by the expansion of our sales team. As a percentage of revenue, SG&A expenses improved to 64.3% compared to 65.7%, reflecting ongoing cost-containment efforts and improvements in sales force productivity. R&D expenses increased to $238,000, from $57,000 in Q2 FY 2018, due to work on an innovative product feature designed to improve patients’ access to treatment adherence data.
Operating income totaled $672,000, compared to $771,000 in Q2 FY 2018.
Net income before income tax expense totaled $689,000 compared to $766,000 in Q2 FY 2018.
Net income equaled $378,000, or $0.04 per diluted share, compared to $420,000, or $0.05 per diluted share, in Q2 FY 2018. In Q2 FY 2019, income tax expense totaled $311,000, compared to $346,000 in the same period of the prior year.
“We remain dedicated to achieving double digit top-line growth and expect improved bottom-line results over the next few years through diligent execution of our growth strategy, enhanced sales force productivity and tighter expense management,” Ms. Skarvan added. “Our sales team is hyper-focused on strategic accounts and visit frequency within each of our territories to drive further market share gains. Moreover, we are intensifying our efforts to secure home care referrals from hospitals, which have powerful economic incentives to prescribe SmartVest at the time patients are discharged to avoid costly readmission penalties under the Affordable Care Act. With continued progress in these areas, we see a tremendous opportunity to gain share in the large and growing bronchiectasis market.”
Year-to-Date FY 2019 Summary
For the six months ended December 31, 2018, revenue grew 15.2% to $15.3 million, from $13.3 million in the same period of fiscal 2018, driven by a 13.3% increase in home care revenue. Gross margins were 75.9%, compared to 76.1% in the prior fiscal year, while net income was approximately $532,000, or $0.06 per diluted share, compared to approximately $501,000, or $0.06 per diluted share, in the first six months of fiscal 2018.
The Company’s balance sheet at December 31, 2018 included cash of $7.2 million, compared to $6.8 million at the same time a year earlier, working capital of $19.9 million, and shareholders’ equity of $23.8 million. During the quarter, the Company utilized cash to repay the required balloon payment of approximately $1,085,000 to satisfy the balance of our term debt. As a result of this payment, the Company now has no long-term debt.
Management will host a conference call on February 13, 2019 at 8:00 am CT (9:00 am ET) to discuss Q2 FY 2019 financial results and other matters.
Interested parties may participate in the call by dialing:
The conference call will also be accessible via the following link:
For those who cannot listen to the live broadcast, an online webcast replay will be available in the Investor Relations section of the Company’s web site at: http://investors.smartvest.com/
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. The Company is headquartered in New Prague, Minnesota and was founded in 1992. Further information about the Company can be found at www.smartvest.com.
Certain statements in this release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “believe,” “estimate,” “expect,” “may,” “plan” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for the Company include, but are not limited to: the competitive nature of our market; risks associated with expansion into international markets; changes to Medicare, Medicaid, or private insurance reimbursement policies; new drug or pharmaceutical discoveries; changes to health care laws; changes affecting the medical device industry; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; our ability to protect and expand our intellectual property portfolio; our ability to renew our line of credit or obtain additional credit as necessary; our ability to develop new sales channels for our product; and general economic and business conditions, as well as other factors described from time to time in our reports to the Securities and Exchange Commission (including the Company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent reports on Form 10-Q and Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this release.
Condensed Balance Sheets
|December 31, 2018||June 30, 2018|
|Accounts receivable (net of allowances for doubtful accounts of $45,000)||11,937,466||11,811,308|
|Prepaid expenses and other current assets||329,327||751,541|
|Income tax receivable||24,860||-|
|Total current assets||23,020,515||23,281,879|
|Property and equipment, net||2,875,807||3,091,242|
|Finite-life intangible assets, net||618,034||649,103|
|Deferred income taxes||361,000||364,000|
|Liabilities and Shareholders’ Equity|
|Current maturities of long-term debt||$||-||$||1,101,043|
|Income taxes payable||-||397,390|
|Other accrued liabilities||372,494||464,357|
|Total current liabilities||3,071,070||4,803,283|
|Commitments and Contingencies|
Common stock, $0.01 par value; authorized: 13,000,000 shares; 8,384,184 and 8,288,659
issued and outstanding at December 31, 2018 and June 30, 2018, respectively
|Additional paid-in capital||15,641,714||14,953,103|
|Total shareholders’ equity||23,810,543||22,588,848|
|Total liabilities and shareholders’ equity||$||26,881,613||$||27,392,131|
Condensed Statements of Operations
For the Three Months Ended
For the Six Months Ended
|Cost of revenues||1,950,040||1,560,427||3,683,039||3,174,032|
|Selling, general and administrative||5,152,394||4,575,172||10,428,148||9,096,076|
|Research and development||237,838||56,794||306,028||127,458|
|Total operating expenses||5,390,232||4,631,966||10,734,176||9,223,534|
|Interest income (expense), net||16,521||(4,894||)||29,974||(9,093||)|
|Net income before income taxes||688,736||765,757||901,129||860,707|
|Income tax expense||311,000||346,000||369,000||360,000|
|Income per share:|
|Weighted-average common shares outstanding:|
Condensed Statements of Cash Flows
|Six Months Ended December 31,|
|Cash Flows From Operating Activities|
|Adjustments to reconcile net income to net cash provided by operating activities:|
|Amortization of finite-life intangible assets||$||59,863||$||56,610|
|Amortization of debt issuance costs||$||1,958||$||4,394|
|Share-based compensation expense||$||500,745||$||386,248|
|Loss on disposal of property and equipment||$||1,198||$||-|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other assets||$||421,864||$||4,074|
|Income tax receivable||$||(24,860||)||$||-|
Income tax payable
|Accounts payable and accrued liabilities||$||(233,780||)||$||(153,824||)|
|Net cash provided by operating activities||$||820,589||$||1,529,783|
|Cash Flows From Investing Activities|
|Expenditures for property and equipment||$||(122,337||)||$||(228,176||)|
|Expenditures for finite-life intangible assets||$||(28,794||)||$||(10,038||)|
|Net cash used in investing activities||$||(151,131||)||$||(238,214||)|
|Cash Flows From Financing Activities|
|Principal payments on long-term debt including capital lease obligations||$||(1,103,001||)||$||(25,041||)|
|Issuance of common stock upon exercise of options||$||188,821||$||-|
|Net cash used in financing activities||$||(914,180||)||$||(25,041||)|
|Net (decrease) increase in cash||$||(244,722||)||$||1,266,528|
|Beginning of period||$||7,455,844||$||5,573,709|
|End of period||$||7,211,122||$||6,840,237|
Jeremy Brock, Chief Financial Officer
The Equity Group Inc.
Kalle Ahl, CFA
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...